Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective

Advances in Medical Sciences

Volumn 60, Issue 1, 2015, Pages 76-82

  Lewczuk, Piotr ^a   Mroczko, Barbara ^b   Fagan, Anne ^c   Kornhuber, Johannes ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid Tau; Cerebrospinal fluid; Clinical neurochemistry

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; PITTSBURGH COMPOUND B; TAU PROTEIN; THK 5105 F 18; TRACER; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN;

ALGORITHM; ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; AMYLOID PLAQUE; BACTERIAL MENINGITIS; BRAIN ATROPHY; CEREBROSPINAL FLUID; COGNITIVE DEFECT; COMORBIDITY; CORTICOBASAL DEGENERATION; CREUTZFELDT JAKOB DISEASE; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DOWN SYNDROME; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HUMAN; LUMBAR PUNCTURE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOMERIZATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME; ANIMAL; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOMARKERS; HUMANS; MILD COGNITIVE IMPAIRMENT; TAU PROTEINS;

EID: 84927605569     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.1016/j.advms.2014.11.002     Document Type: Review

References (91)

1. Thies W, Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011;7(March (2)):208-44.
2. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010;17(October (10)):1236-48.
3. 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010;6(March (2)):158-94.
4. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011;7(March (3)):137-52.
5. Pena-Longobardo LM, Oliva-Moreno J. Economic valuation and determinants of informal care to people with Alzheimer's disease. Eur J Health Econ 2014. http://dx.doi.org/10.1007/s10198-014-0604-6.
6. de Leon MJ, Golomb J, George AE, Convit A, Tarshish CY, McRae T, et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal forma-tion. AJNR Am J Neuroradiol 1993;14(July-August (4)):897-906.
7. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368(Ju-ly (9533)):387-403.
8. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18(July-August (4)):351-7.
9. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 2001;98(September (19)):10966-71.
10. Price JL, Morris JC. Tangles and plaques in nondemented aging and ''preclini-cal'' Alzheimer's disease. Ann Neurol 1999;45(March (3)):358-68.
11. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6(August (8)):734-46.
12. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010;74(January (3)):201-9.
13. Torpy JM, Lynm C, Glass RM. JAMA patient page. Mild cognitive impairment. JAMA 2009;302(July (4)):452.
14. Aluise CD, Sowell RA, Butterfield DA. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta 2008;1782(October (10)):549-58.
15. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012;71(April (4)):266-73.
16. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82(4):239-59.
17. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325(6106):733-6.
18. Panegyres PK. The amyloid precursor protein gene: a neuropeptide gene with diverse functions in the central nervous system. Neuropeptides 1997;31(6):523-35.
19. Carlsson CM. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. J Alzheimers Dis 2010;20(3):711-22.
20. Taubes G. Neuroscience. Insulin insults may spur Alzheimer's disease. Science 2003;301(July (5629)):40-1.
21. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, et al. Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003;60(June (12)):1899-903.
22. Karczewska-Kupczewska M, Lelental N, Adamska A, Nikolajuk A, Kowalska I, Gorska M, et al. The influence of insulin infusion on the metabolism of amyloid beta peptides in plasma. Alzheimers Dement 2013;9(July (4)): 400-5.
23. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Ab42, Ab42/Ab40 ratio and total tau. Neurobiol Aging 2004;25(March (3)): 273-81.
24. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011;121(May (5)):597-609.
25. Lewczuk P, Kornhuber J. Neurochemical dementia diagnostics in Alzheimer's disease: where are we now and where are we going? Expert Rev Proteomics 2011;8(August (4)):447-58.
26. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59(March (3)):512-9.
27. Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, et al. β Amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 2003;54(August (2)):263-7.
28. Sjögren M, Gisslen M, Vanmechelen E, Blennow K. Low cerebrospinal fluid βamyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci Lett 2001;314(1/2):33-6.
29. Spies PE, Verbeek MM, van Groen T, Claassen JA. Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease. Front Biosci (Landmark Ed) 2012;17:2024-34.
30. Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, et al. The amyloid-b (Ab) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Ab peptide. Rapid Commun Mass Spectrom 2003;17(12):1291-6.
31. Tapiola T, Soininen H, Pirttila T. CSF tau and Abeta42 levels in patients with Down's syndrome. Neurology 2001;56(April (7)):979-80.
32. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel poten-tial biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2010;15(February (2)):138-45.
33. Lewczuk P, Popp J, Lelental N, Kö lsch H, Maier W, Kornhuber J, et al. Cerebro-spinal fluid soluble amyloid-beta protein precursor as a potential novel biomarkers of Alzheimer's disease. J Alzheimers Dis 2012;28(January (1)):119-25.
34. Perez A, Morelli L, Cresto JC, Castano EM. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 2000;25(February (2)):247-55.
35. Wang-Dietrich L, Funke SA, Kuhbach K, Wang K, Besmehn A, Willbold S, et al. The amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. J Alzheimers Dis 2013;34(January (4)):985-94.
36. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33(August (1)):95-130.
37. Hanger DP, Lau DH, Phillips EC, Bondulich MK, Guo T, Woodward BW, et al. Intracellular and extracellular roles for tau in neurodegenerative disease. J Alzheimers Dis 2014;40:S37-45.
38. Shahani N, Brandt R. Functions and malfunctions of the tau proteins. Cell Mol Life Sci 2002;59(October (10)):1668-80.
39. Karch CM, Jeng AT, Goate AM. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J Biol Chem 2012;287(December (51)):42751-62.
40. Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 2013;14(April (4)):389-94.
41. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012;71(May (5)):362-81.
42. Sahara N, Ren Y, Ward S, Binder LI, Suhara T, Higuchi M. Tau oligomers as potential targets for early diagnosis of tauopathy. J Alzheimers Dis 2014;40:S91-6.
43. Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225(April (3)):210-2.
44. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanme-chelen E, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001;297(January (3)):187-90.
45. Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001;50(2):150-6.
46. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci 2004;23(1/2):115-22.
47. Vanmechelen E, Van Kerschaver E, Blennow K, De Deyn PP, Gartner FH, Parnetti L, et al. CSF-phospho-tau (181P) as a promising marker for discrimi-nating Alzheimer's disease from dementia with Lewy bodies. In: Iqbal K, Sisodia SS, Winblad B, editors. Alzheimer's disease: advances in etiology, pathogenesis and therapeutics. Chichester: John Wiley and Sons Ltd.; 2001. p. 285-91.
48. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's dis-ease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 2001;22(February (1)):77-8.
49. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Ab42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001; 24(1-3):87-97.
50. Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 2000;166(November (1)):201-3.
51. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5(March (3)):228-34.
52. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cogni-tive impairment. JAMA 2009;302(July (4)):385-93.
53. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for pre-diction of Alzheimer's disease. Neurosci Lett 2003;352(November (1)):67-9.
54. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebro-spinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64(March (3)):343-9.
55. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, et al. CSF tau/ Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007;69(August (7)):631-9.
56. Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging 2008;29(June (6)):812-8.
57. Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9(January (1)):119-28.
58. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62(November (11)):1087-95.
59. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007;8(Septem-ber (9)):663-72.
60. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrim-ination and cognitive correlations. Neurology 2009;73(July (4)):287-93.
61. Storandt M, Head D, Fagan AM, Holtzman DM, Morris JC. Toward a multifac-torial model of Alzheimer disease. Neurobiol Aging 2012;33(October (10)):2262-71.
62. Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J. Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J Neural Transm 2009;116(September (9)):1163-7.
63. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using βamyloid(1- 42) and tau levels in CSF. Neurology 1999;52(8):1555-62.
64. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J. Amyloid b 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. J Alzheimers Dis 2015;43(1):183-91. http://dx.doi.org/10.3233/JAD-140771.
65. Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem 2007;101(May (4)):1053-9.
66. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp Neurol 2010;223(June (2)): 366-70.
67. Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, et al. International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 2006;409(November (1)):1-4.
68. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(May (3)):263-9.
69. Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(May (3)):257-62.
70. McKhann GM. Changing concepts of Alzheimer disease. JAMA 2011;305(June (23)):2458-9.
71. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(May (3)):270-9.
72. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(May (3)):280-92.
73. S3-Leitlinie ''Demenzen''. http://www.dggpp.de/documents/s3-leitlinie- demenz-kf.pdf; 2009.
74. Morris JC, Blennow K, Froelich L, Nordberg A, Soininen H, Waldemar G, et al. Harmonized diagnostic criteria for Alzheimer's disease: recommendations. J Intern Med 2014;275(March (3)):204-13.
75. Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, et al. (18)FFDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J Nucl Med 2007;48(July (7)):1129-34.
76. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2(April (4)). http://dx.doi.org/ 10.1101/cshperspect.a006213.
77. Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 2012;33(October (10)):2272-81.
78. Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, et al. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis 2009;16(2):351-62.
79. Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathol-ogy using 18F-THK5105 PET. Brain 2014;137(June (Pt 6)):1762-71.
80. Jagust W. Time for tau. Brain 2014;137(June (Pt 6)):1570-1.
81. Shah M, Catafau AM. Molecular imaging insights into neurodegeneration: focus on Tau PET radiotracers. J Nucl Med 2014;55(May (6)):871-4.
82. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55(March (3)):306-19.
83. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131(June (Pt 6)):1630-45.
84. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29(October (10)):1456-65.
85. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009;65(June (11)):927-34.
86. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009;50(September (9)):1464-70.
87. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009;73(October (15)):1193-9.
88. Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12(October (10)):957-65.
89. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42(July (1)):85-94.
90. Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999;52(May (8)):1687-9.
91. Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008;71(September (10)):743-9.